GlassScriptPhysician profile
Robert M Woodard
NPI 1891705034
$1,629.12
in general payments reported to CMS, 2019-2025
24 companies · $155 in 2025
The $155 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137 · 2020: $41.00 · 2021: $305 · 2022: $260 · 2023: $475 · 2024: $257 · 2025: $155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $887.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $886.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $452.42 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $353.34 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Astellas Pharma US INC | $102.10 | 2021-2024 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $96.13 | 2020-2022 | |
| Amgen INC. | $87.56 | 2022-2024 | Repatha, Otezla |
| Boston Scientific Corporation | $78.33 | 2023-2024 | Watchman Flx, Bodyguardian |
| E.R. Squibb & Sons, L.L.C. | $62.08 | 2023 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $46.99 | 2019-2025 | Breztri |
| Merck Sharp & Dohme LLC | $44.24 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $39.80 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $34.30 | 2023-2025 | Austedo Xr, Austedo Xr |
| Currax Pharmaceuticals LLC | $32.14 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.09 | 2019-2022 | |
| Lilly USA, LLC | $25.27 | 2022 | |
| Irhythm Technologies, INC. | $21.25 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $20.21 | 2023 | Proclaim |
| Horizon Therapeutics Plc | $19.12 | 2023 | Krystexxa |
| Sumitomo Pharma America, INC. | $15.81 | 2023 | Gemtesa |
| Almatica Pharma LLC | $12.98 | 2021 | |
| Allergan, INC. | $12.44 | 2020 | |
| Pfizer INC. | $11.58 | 2019 | |
| Organon LLC | $11.53 | 2023 | Nexplanon |
| Mylan Specialty L.P. | $11.30 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Woodard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.